pipeline and with depression, resistant need, therapeutics patients pain bipolar thank treatment post-traumatic Thank advance continued joining to depression. as us chronic innovative you, for suicidal stress to for you our our and disorders success, including great related disorder everyone psychiatric morning discuss potentially we facing unmet Suzanne. Good of
while compelling continue and brain recent our In corporate results, update. strides franchise, health for will start trials on and we advancing lead our our is clinical as a our a XXXX business we building months, to discuss first shareholders. for science in NRX-XXX build XXXX to great our we've our long-term value continuing off and execute made candidate quarter to provide strategy. great Today, product leading
To summarize, product, Board of potential of independent NRX-XXX to and B unblinded with continue a we in to manufacturing or as of the controls Safety path announced NRX-XXX on of a the the DSMB, commercial our FDA chemistry Type well evaluation and as approval with signals and data findings encouraging and subsequent NRX-XXX and path Suicidal aligned identified FDA stage of first a provided Monitoring meeting. Depression. We in align evaluation for safety or study bipolar Data a whose Treatment-Resistant first on DSMB are based one no Bipolar trials concerns our for we patients recommendation findings, FDA two patients interactions that And clinical indicated consolidating continue futility suicidal depression and the safety to no XX into positive in enrollment. were treated, reported with on
in with depression. these patients depression and an of suicide I'll and a attempt more for X their Data bipolar NMDA dose combination medicine U.S. the for Treatment-Resistant receptor are or treatment pain. progress with this million XX% risk use very chronic begin reviewing bipolar the NRX-XXX D-cycloserine, Suicidal by living lifetime. and that NRX-XXX is standard-of-care There in in is PTSD of approximately Bipolar recent a fixed resistant lurasidone, of regulator indicates made in high Depression, will people suicide population.
believe electroshock life-saving knowledge, treatment depression. a for alternative people first Based To treatment to there labels are who antidepressants warning This attempt whose suicide with advance, bring NRx our on by people is approved only for we that currently of available the bipolar no therapy. populations. currently However, to risk have need potential potentially are significant suicidal address to unmet profile, vulnerable patients in we a increased box approved a for options. to underserved is potential therapeutic is Company medicines regarding medicine because the black FDA NRx's carry differentiated
NMDA suicidal science been drugs suicidal potential symptoms reduce NRX-XXX, for shown to psychiatric neither with Turning have important is shown of nor and an depression ideation, antagonist abuse, when have which to consideration the disorders behind thoughts. lurasidone D-cycloserine treating and
XX these synergy X-HTXA we and as between as a at be have and depression, which system depressive NRx, now At PTSD portfolio critical effective bipolar discovered a discoveries other the been D-cycloserine of in relating the disorder, central dosages resulted well the drugs, in NMDA targeted nervous conditions. of patents XX of major conditions. treatment world, may These which unique issued, around to
data, benefit NRX-XXX acute patients with introduced acute that population showed this in bipolar with on FDA breakthrough stabilization profile Agreement therapeutic administered drug designation Phase proof-of-concept options. initially with X with with clinical SPA following care ketamine, in Based trial, bipolar and data of as no a ideation demonstrated Special suicidality. from which therapy ketamine acute drug NRX-XXX STABIL-B conjunction treatment hospitalized therapy and highly for a patient depression a in NRX-XXX the granted the after a patients, Protocol differentiated We suicidal or
with patients suicidal in the for a bipolar recent a treatment XXXX, a at bipolar of initiated hospitalized behavior. the with severe acute and and NRX-XXX Phase trial meeting study broader comments with B ideation X for acute suicidality, clinical Type this ideation. on from NRX-XXX Based FDA January In much Company study with depression potential registrational the clinical of trial suicidal initiated population. of XXXX has Phase of NRX-XXX depression our X A sub-acute patient been converged for
trial we made lurasidone. of This versus when NRX-XXX in sub-acute encouraging the March population findings outpatient announced of this in year, from was our decision
time XX Our independent unblinded the DSMB examined no trial. the futility found first in from data this patients signal at and
the plan, requires statistically observed advantage significant study not of failure identified no were enrollment DSMB. to an the with analysis the drug by continued yet in relative the must identify According Similarly, recommended the a and statistical that futility trial advantage in NRX-XXX association planned. though DSMB treatment safety investigational signals to to the as the comparator that be
clinical and trial The depression the could a includes bipolar represents converged patient filing in this Xb/X suicidal population, upgraded with prove suicidal be results which believe used we -- of registrational future newly indication, should bipolar study a successful. broader patients trial Phase the
depression under unmet this outpatient available have for those of trial who greatest clinical In medicines. we focused of physician trial, those of ongoing patients thoughts needs, our depressive and the who care treatment first symptoms bipolar specifically have of on active and medical despite self-harm are
NRx's significantly improve suicidality this to use that available of care our symptoms six expert to potentially a the of a controlled a medicines. multicenter of expand registrational depression suffer to has anticipate with nearly medicine weeks market basis. million and and who potential X on We objective of $X.X double-blind use currently medical randomized people The from This demonstrate severe year. the currently the taken over home study this to twice study when is ability ideation despite suicidal approximately depression is a billion day
option bipolar could trials in with XXXX. may strategy Xb/X Phase Data of more coming ongoing This the from commercialization recommendations. up The indication expected significant quarter suicidal therapy Company broader this clinical believes also with indication the clinical FDA's patients the and trials in fourth matter in enable the in the advantages are consistent years. the an the outpatient of broaden the that depression, converge ongoing
XXXX, FDA reached proposed a January C based in our manufacturing our meeting on alignment manufacturing Importantly, also on review we with controls. chemistry Type plan to the and
patients to NRX-XXX now result, Right positioned unable make of NRX-XXX have conduct who treatment As trials to programs approved NRx expanded access for options. and Try registrational exhausted a available through is to
for We lead this of Submission, to milestone. In ready a review are development excited can approval studies. bridging designation, the under as without potential about adopting we commercial breakthrough believe more seamless this a process manufacturing and our process particular, therapy at the stage that NDA need
rating. and A technical their the believes whose ratings this the language was primary in The be or all its that the of for site efficacy study each ability quarter refined for relies This rates can site clinical monitor between of of of a rating met are upon team better both Company train who trial. that XXXX, to Company's validate During ratings and for management psychometric assess independent XX% standard standard the were the the duration quality obtained veteran used the concordance the first to team endpoints raters maintained participants veteran was trial. and set raters. the standard of Company
a conducts to trials, trial. has clinical to randomize with The and April to to the for research and clinical Science U.S. organization Company contracted to identified treated voice-of-the-patient enroll with disclosed national may bipolar campaign recruitment the XnHealth to be sufficient states a have previously XX, on its initiative focus In up trial XX has cover the reach in to recruitment that XXX,XXX clinical by similarly engaged participants enlarged suicidality. Company broadened within who organization relationship contract this trial. the publicize decentralized broadened depression XnHealth XnHealth recruit the that indicated subscribers with a a plus to initiate participants XXXX, them the additionally
we to unmet PTSD, suicide. our of of stress depression for disorder XX Approximately million our experiencing experienced PTSD in drive with associated Depression post-traumatic area in which conditions. country and Forces may NRX-XXX Additionally, similar lost another to driven pathways severe of to Between our or and in have last work PTSD other suicidality. medical PTSD high Veterans continued quarter need, by one-third with suicidality. X that and XX% that day advance those also is plans are to individual XX are every members be Armed development
class may a PTSD. in specific particular, of as D-cycloserine, antagonist a NMDA effect However, treatment more and in have
the in of events, recurring PTSD PTSD. used also others to traumatic This preclinical has similarly as been demonstrated ketamine. a known of document fear WKY effect a validated PTSD-specific model extinguish In ability memory, images to by of D-cycloserine, a model study,
specific PTSD it not of trial. compared PTSD to investigational has scores out in not specific symptoms. also directly randomized and in Today, and addictive, Unlike is drug effect is psychedelic reduce side-effect itself. component antidepressant however, hope will and will we symptoms ketamine there clinical our We for effect PTSD memory IV ketamine, show caused fear Repeated of approved PTSD NRX-XXX a has these anticipate neurotoxic been to on that of controlled improve not medicine placebo demonstrated trial. and PTSD that no demonstrate
a initiate NRX-XXX study in to on-track are XXXX. and of PTSD We
registered about initiation protocol self-harm. resistant in programs, studying of support risk excited incredibly a NRX-XXX's the for $X.X we million safety of are close bipolar and and clinical with treatment specifically continued expanded of access more our potential database the order an of effect to announced of efforts a life-saving to We support and offering development pipeline direct these NRX-XXX, depression
our for registrational us psychiatric indication And commitment in all data financial on forward the to existing based division existing come. to the trials allows you to our successful. potential from people database update we B clinical investigate disorders living look their expanded trial. FDA's providing continued an The commercially with This the ongoing with by and of in support serious meeting and to our NRX-XXX forward become demonstrates the activity Type to CNS of months our shareholders our put
achieved of or until the issuance bipolar patent In have major position patent suffering at We without significant property strengthens the milestones with which depression received NRX-XXX, least This recent February, suicidality. corporate months. intellectual including the or in patients of depression NRX-XXX the to for of the use we treat of Company's U.S. covers depression number from XXXX. notice
the class published bench one of Family Professor to of of at disease. board Harvard psychiatrists research, the particularly to School, is the Research a Director deep Chair, healthcare world's He Nierenberg executives Marion Hospital. Nierenberg is scientists our it Professor at strengthened in Psychiatry and in Leboyer, world Professor, area recent Andrew for Bipolar the announced appointment of in relates months. and Massachusetts of as advisory our March. also Medical most Dauten the Center Professor, We General and is psychiatric bipolar of We
suicidal trial are honoured depression. to We in have ongoing clinical our investigator bipolar him of principal as
autism. relates to of in field leading neuropsychiatry, France's disease particularly extensively an and as is Leboyer bipolar one it of researcher published psychiatrist, Professor the
suicidality In website. Professor Fundamental psychiatry acute the facilitated depression. has biographies and on an patients, Fondation their patients to her collaboration about Please chairs bipolar addition NRx and studying of important particularly our academic hospital for researchers, ketamine see between the Leboyer with French achievements, treatment
needs established funding address Also, parallel, on continued in approval commercialization dialogue debt strategic trial. Company clinical with to our the drug current the has to current the LLC, facility Capital product. and ongoing has of the Company's focused Company the engage best In the Company's conversation of ongoing to a debt the support an lender, Streeterville
for in foundation with strong clinical lives a trials of achieved have disorders. difference life threatening efficiently advance that we NRx the that enables confident are We psychiatric patients make to our and us a
to support. like NRx the express my trial to gratitude and would team, I investigators continued with patients, the our shareholders clinical
to brief turn over our results. With overview that, I'll it Seth a of for financial
